share_log

Raymond James Downgrades VBI Vaccines to Outperform, Lowers Price Target to $2

Benzinga Real-time News ·  Nov 11, 2022 06:36

Raymond James analyst Steven Seedhouse downgrades VBI Vaccines (NASDAQ:VBIV) from Strong Buy to Outperform and lowers the price target from $5 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment